Incidental detection in the DANCAVAS trial was limited by design and did not bias the cost effectiveness conclusion

Eur Heart J. 2023 Jan 1;44(1):70. doi: 10.1093/eurheartj/ehac646.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Cardiovascular Diseases*
  • Cardiovascular System*
  • Cost-Benefit Analysis
  • Cost-Effectiveness Analysis
  • Denmark
  • Humans